|
[이데일리 노희준 기자] Announced on the 23rd that it has signed a technology transfer contract for its high-efficiency cell culture platform technology (MLSC) that can be applied as a raw material cell for gene cell therapy products. According to the agreement, the two companies decided to not disclose the contract size.
Under this contract, Medipost decided to hand over the license to LG Chem for product development and commercialization using related technologies such as high-efficiency mesenchymal stem cells and MLSC, a high-efficiency cell culture platform technology.
LG Chem is planning to expand the development of an innovative gene cell therapy pipeline that incorporates its own gene technology, using the underlying technology of Medipost.
Under this contract, Medipost will receive an advance deposit with no return condition. In the future, LG Chem will receive milestones according to sales in the event of global clinical development progress and commercialization, and additionally receive current royalty based on net sales.
LG Chem will own the worldwide exclusive development and commercialization rights for gene cell therapy products discovered through joint research by the two companies. The two companies decided not to disclose specific down payments, milestones, and total contract size.
Since the end of 2018, the two companies have signed a joint research contract to discover new drug candidates and have jointly conducted basic research to develop gene cell therapy products. This technology transfer contract was conducted as a follow-up contract according to the research results of open innovation (open innovation) of both companies.
Yang Yun-seon, CEO of Medipost, said, “Because this technology transfer is the transfer of the license for the cell culture open platform technology, it is possible to develop our own pipeline as well as to transfer additional technologies to other companies. It will speed up even more.”
LG Chem Sohn Ji-woong, head of the Life Science Business Division, said, “Through two years of joint research with Medipost, which has the best capability in the field of stem cells, we have confirmed the possibility of developing an innovative gene cell therapy product. “We plan to launch innovative new drug-level products that can fundamentally treat diseases in high demand in the global market.”